Table of Contents
1. Executive Summary
2. Market Background and Classifications
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. Market Trends and Forecast Analysis from 2014 to 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Biopharmaceutical Contract Manufacturing Market Trends and Forecast
3.3: Global Biopharmaceutical Contract Manufacturing Market by Product
3.3.1: Biologics
3.3.1.1: Monoclonal Antibodies (MAbs)
3.3.1.2: Recombinant Proteins
3.3.1.3: Vaccines
3.3.2: Antisense, RNAi, & Molecular Therapy
3.3.3: Biosimilars
3.4: Global Biopharmaceutical Contract Manufacturing Market by Service
3.4.1: Process Development
3.4.1.1: Downstream
3.4.1.2: Upstream
3.4.2: Fill & Finish Operations
3.4.3: Analytical & QC Studies
3.4.4: Packaging
3.5: Global Biopharmaceutical Contract Manufacturing Market by Therapeutic Area
3.5.1: Autoimmune Disease
3.5.2: Oncology
3.5.3: Metabolic Disease
3.5.4: Opthalmology
3.5.5: Cardiovascular Disease
3.5.6: Infectious Disease
3.5.7: Neurology
3.5.8: Respiratory Disorder
3.5.9: Others
3.6: Global Biopharmaceutical Contract Manufacturing Market by Source
3.6.1: Mammalian
3.6.2: Non-Mammalian
3.7: Global Biopharmaceutical Contract Manufacturing Market by Application
3.7.1: Commercial
3.7.2: Clinical
4. Market Trends and Forecast Analysis by Region
4.1: Global Biopharmaceutical Contract Manufacturing Market by Region
4.2: North American Biopharmaceutical Contract Manufacturing Market
4.2.1: Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, and Vaccines), Antisense, RNAi, & Molecular Therapy, and Biosimilars
4.2.2: Market by Service: Process Development (Downstream and Upstream), Fill & Finish Operations, Analytical & QC Studies, and Packaging
4.2.3: Market by Therapeutic Area: Autoimmune Disease, Oncology, Metabolic Disease, Opthalmology, Cardiovascular Disease, Infectious Disease, Neurology, Respiratory Disorder, and Others
4.2.4: Market by Source: Mammalian and Non-Mammalian
4.2.5: Market by Application: Commercial and Clinical
4.2.6: The United States Biopharmaceutical Contract Manufacturing Market
4.2.7: The Canadian Biopharmaceutical Contract Manufacturing Market
4.2.8: The Mexican Biopharmaceutical Contract Manufacturing Market
4.3: European Biopharmaceutical Contract Manufacturing Market
4.3.1: Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, and Vaccines), Antisense, RNAi, & Molecular Therapy, and Biosimilars
4.3.2: Market by Service: Process Development (Downstream and Upstream), Fill & Finish Operations, Analytical & QC Studies, and Packaging
4.3.3: Market by Therapeutic Area: Autoimmune Disease, Oncology, Metabolic Disease, Opthalmology, Cardiovascular Disease, Infectious Disease, Neurology, Respiratory Disorder, and Others
4.3.4: Market by Source: Mammalian and Non-Mammalian
4.3.5: Market by Application: Commercial and Clinical
4.3.6: The Biopharmaceutical Contract Manufacturing Market of United Kingdom
4.3.7: The German Biopharmaceutical Contract Manufacturing Market
4.3.8: The French Biopharmaceutical Contract Manufacturing Market
4.4: APAC Biopharmaceutical Contract Manufacturing Market
4.4.1: Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, and Vaccines), Antisense, RNAi, & Molecular Therapy, and Biosimilars
4.4.2: Market by Service: Process Development (Downstream and Upstream), Fill & Finish Operations, Analytical & QC Studies, and Packaging
4.4.3: Market by Therapeutic Area: Autoimmune Disease, Oncology, Metabolic Disease, Opthalmology, Cardiovascular Disease, Infectious Disease, Neurology, Respiratory Disorder, and Others
4.4.4: Market by Source: Mammalian and Non-Mammalian
4.4.5: Market by Application: Commercial and Clinical
4.4.6: The Chinese Biopharmaceutical Contract Manufacturing Market
4.4.7: The Indian Biopharmaceutical Contract Manufacturing Market
4.4.8: The Japanese Biopharmaceutical Contract Manufacturing Market
4.5: ROW Biopharmaceutical Contract Manufacturing Market
4.5.1: Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, and Vaccines), Antisense, RNAi, & Molecular Therapy, and Biosimilars
4.5.2: Market by Service: Process Development (Downstream and Upstream), Fill & Finish Operations, Analytical & QC Studies, and Packaging
4.5.3: Market by Therapeutic Area: Autoimmune Disease, Oncology, Metabolic Disease, Opthalmology, Cardiovascular Disease, Infectious Disease, Neurology, Respiratory Disorder, and Others
4.5.4: Market by Source: Mammalian and Non-Mammalian
4.5.5: Market by Application: Commercial and Clinical
4.5.6: Brazilian Biopharmaceutical Contract Manufacturing Market
5. Competitor Analysis
5.1: Market Share Analysis
5.2: Product Portfolio Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. Cost Structure Analysis
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. Growth Opportunities and Strategic Analysis
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Biopharmaceutical Contract Manufacturing Market by Product
7.1.2: Growth Opportunities for the Global Biopharmaceutical Contract Manufacturing Market by Service
7.1.3: Growth Opportunities for the Global Biopharmaceutical Contract Manufacturing Market by Therapeutic Area
7.1.4: Growth Opportunities for the Global Biopharmaceutical Contract Manufacturing Market by Source
7.1.5: Growth Opportunities for the Global Biopharmaceutical Contract Manufacturing Market by Application
7.1.6: Growth Opportunities for the Global Biopharmaceutical Contract Manufacturing Market by Region
7.2: Emerging Trends in the Global Biopharmaceutical Contract Manufacturing Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Biopharmaceutical Contract Manufacturing Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Biopharmaceutical Contract Manufacturing Market
7.3.4: Certification and Licensing
8. Company Profiles of Leading Players
8.1: Lonza Group Ltd.
8.2: Inno Biologics Sdn Bhd
8.3: Rentschler Biotechnologie GmbH
8.4: JRS Pharma
8.5: AGC Biologics
8.6: ProBioGen
8.7: Fujifilm Diosynth Biotechnologies U.S.A., Inc.
8.8: Toyobo Co., Ltd.
8.9: Samsung BioLogics
8.10: Thermo Fisher Scientific, Inc.